Proof-of-concept studies with a computationally designed M pro inhibitor as a synergistic combination regimen alternative to Paxlovid is a research paper published in Proceedings of the National Academy of Sciences (2024). On theSindex it has a DataRank of 0.425. It has been cited 16 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →HHS | NIH | National Institute of General Medical Sciences
Grant: GM032136
HHS | National Institutes of Health
Grant: R24OD026440
HHS | NIH | NIAID | Division of Intramural Research
Grant: 1U19AI171443
HHS | NIH | National Institute of General Medical Sciences
Grant: T32 GM148333
NIAID NIH HHS
Grant: U19 AI171443
NIH HHS
Grant: S10 OD021527
NIGMS NIH HHS
Grant: P30 GM133893
NIGMS NIH HHS
Grant: R01 GM032136
NIGMS NIH HHS
Grant: P30 GM124165
FWCI
4.10
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals